FY2017 EPS Estimates for AxoGen, Inc. (AXGN) Boosted by Cantor Fitzgerald

AxoGen, Inc. (NASDAQ:AXGN) – Equities research analysts at Cantor Fitzgerald raised their FY2017 earnings estimates for shares of AxoGen in a note issued to investors on Tuesday. Cantor Fitzgerald analyst T. Steed now expects that the medical equipment provider will post earnings of ($0.28) per share for the year, up from their previous forecast of ($0.30). Cantor Fitzgerald currently has a “Overweight” rating and a $18.00 target price on the stock.

A number of other analysts have also recently weighed in on AXGN. BidaskClub cut shares of AxoGen from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Leerink Swann started coverage on shares of AxoGen in a research report on Monday, July 31st. They issued an “outperform” rating and a $22.00 price objective for the company. ValuEngine raised shares of AxoGen from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Wedbush reissued an “outperform” rating and issued a $14.00 price objective (down from $17.00) on shares of AxoGen in a research report on Friday, May 19th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. AxoGen currently has a consensus rating of “Buy” and an average price target of $15.90.

COPYRIGHT VIOLATION WARNING: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/08/12/fy2017-eps-estimates-for-axogen-inc-axgn-boosted-by-cantor-fitzgerald.html.

Shares of AxoGen (NASDAQ:AXGN) opened at 15.10 on Thursday. The firm has a 50-day moving average price of $15.85 and a 200-day moving average price of $12.90. The firm’s market capitalization is $501.92 million. AxoGen has a 1-year low of $7.65 and a 1-year high of $17.25.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The company had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $14.40 million. During the same period last year, the firm earned ($0.09) earnings per share. AxoGen’s quarterly revenue was up 46.2% on a year-over-year basis.

A number of institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. boosted its position in AxoGen by 238.7% in the second quarter. Russell Investments Group Ltd. now owns 611,678 shares of the medical equipment provider’s stock worth $10,245,000 after buying an additional 431,057 shares during the last quarter. Lyon Street Capital LLC purchased a new position in AxoGen during the first quarter worth $2,166,000. Renaissance Technologies LLC purchased a new position in AxoGen during the first quarter worth $1,473,000. EAM Investors LLC boosted its position in AxoGen by 86.7% in the second quarter. EAM Investors LLC now owns 293,880 shares of the medical equipment provider’s stock worth $4,922,000 after buying an additional 136,453 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC boosted its position in AxoGen by 26.5% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 559,516 shares of the medical equipment provider’s stock worth $5,847,000 after buying an additional 117,178 shares during the last quarter. 64.58% of the stock is owned by institutional investors.

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

What are top analysts saying about AxoGen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AxoGen Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit